Key result
Apigenin plus doxorubicin augments cytotoxicity, cutting HepG2 cell viability by ~47% versus doxorubicin alone.
Why the study?
Systemic doxorubicin provides only marginal survival improvements in hepatocellular carcinoma, prompting evaluation of natural flavonoids to enhance doxorubicin cytotoxicity against HepG2 cells.
Do natural flavonoids augment the cytotoxicity of doxorubicin against human hepatocellular carcinoma cell line HepG2?
Population
Human hepatocellular carcinoma cell line HepG2
Comparison
Doxorubicin combined with various natural flavonoids vs single treatments
Design
In vitro laboratory study
Authors
Loading...
May sensitize HepG2 cells to doxorubicin via non-oxidative mechanisms; leaves open clinical translation in HCC chemoembolization.
Do natural flavonoids augment the cytotoxicity of doxorubicin against human hepatocellular carcinoma cell line HepG2?
Absolute Event Rate: 35.62% vs 67.77%
p-value: p=≤0.05
Apigenin and hesperidin augment the cytotoxic effect of doxorubicin against HepG2 cells, suggesting a potential role in hepatocellular carcinoma therapy.
Korga-Plewko et al. (2019) studied Hepatocellular carcinoma (HepG2 cells). Apigenin and hesperidin with doxorubicin vs. Doxorubicin alone or control was evaluated on Cell viability (p=≤0.05). Apigenin and hesperidin significantly augmented the cytotoxicity of doxorubicin against HepG2 cells, with the doxorubicin and apigenin combination reducing cell viability to 35.62% compared to 67.77% with doxorubicin alone.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: